Filing summary
Company: Psyence Biomedical Ltd. Filing: Form 6-K, furnished October 5, 2026, for the month of October 2026. The company indicates it files annual reports on Form 20-F.
Business context
The filing furnishes an October 5, 2026 press release titled “Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine.” The press release itself is identified as Exhibit 99.1, but its text is not included in the provided filing content.
Financial information and outlook
The provided text contains no revenue, profit, cash flow, margin, debt, liquidity, guidance, or other financial metrics. It provides no details on the partnership’s terms, costs, timing, production capacity, regulatory status, or expected financial impact.
Key facts to verify
- Review Exhibit 99.1 for the partnership’s scope, terms, milestones, and expected costs or financial effects.
- Verify the manufacturing plans, regulatory requirements, and any approvals or other contingencies associated with pharmaceutical-grade ibogaine production.